Abstracts tagged "Compliance"

Abstract Number: 3153 • 2016 ACR/ARHP Annual Meeting
Automated Cell Phone Monitoring of Disease Activity and Medication Adherence in Early Rheumatoid Arthritis
Laura Kuusalo^1,2, Hannu Kautiainen³, Tuulikki Sokka-Isler⁴, Toini Uutela⁵, Laura Pirilä², Timo Yli-Kerttula⁶, Markku J Kauppi^7,8, Tuomas Rannio⁹, Kirsi Paalanen¹⁰, Arto Kokko⁹, Juha Asikainen⁹, Jelena Borodina¹⁰, Johanna Paltta², Kari Laiho¹¹, Andrus Mullanmaa¹², Kari Puolakka¹² and SandRA Study Group, ¹University of Turku, Turku, Finland, ²Turku University Hospital, Turku, Finland, ³Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁴Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁵Lapland Central Hospital, Rovaniemi, Finland, ⁶Sairaalantie 3, Satakunta Central Hospital, Rauma, Finland, ⁷School of Medicine, University of Tampere, Tampere, Finland, ⁸Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁹Jyvaskyla Central Hospital, Jyväskylä, Finland, ¹⁰Jyvaskyla Central Hospital, Jyvaskyla, Finland, ¹¹Päijät-Häme Central Hospital, Lahti, Finland, ¹²South Karelia Central Hospital, Lappeenranta, Finland
Background/Purpose: Remission targeted treatment of early RA requires frequent monitoring. However, in clinical practice monitoring frequency is not always optimal due to factors like limited…
Abstract Number: 525 • 2016 ACR/ARHP Annual Meeting
Predictors of Health Care Drop-out in an Inception Cohort of Patients with Early Onset Rheumatoid Arthritis
Irazú Contreras-Yáñez¹ and Virginia Pascual-Ramos², ¹Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Mexican Accreditation Council of Rheumatology, A.C., Mexico City, Mexico
Background/Purpose: The impact of inadequate therapy behavior in rheumatoid arthritis (RA) patient outcomes may be amplified by the fact that almost all individuals with poor…
Abstract Number: 3195 • 2016 ACR/ARHP Annual Meeting
Patterns and Predictors of Hydroxychloroquine Nonadherence in a Nationwide Cohort of Medicaid Beneficiaries with Systemic Lupus Erythematosus
Candace H. Feldman¹, Jamie E. Collins², Zhi Zhang³, Daniel H. Solomon⁴, Karen H. Costenbader¹ and Ichiro Kawachi⁵, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham & Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁵Social and Behavioral Sciences, Harvard T. H. Chan School of Public Health, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is the standard of care medication for most SLE patients, however cross-sectional studies suggest that nonadherence is common. Similar to the fluctuating…
Abstract Number: 531 • 2016 ACR/ARHP Annual Meeting
Disease Activity and Physical Fatigue As Related to Adherence and Health Literacy in Patients with Rheumatoid Arthritis
Jens Gert Kuipers¹, Michael Koller², Florian Zeman², Karolina Mueller³ and Ulrich Rueffer⁴, ¹Department of Rheumatology, Red Cross Hospital Bremen, Bremen, Germany, ²Center of Clinical Studies, University Hospital Regensburg, Regensburg, Germany, ³Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany, ⁴German Fatigue Society, Cologne, Germany
Disease activity and physical fatigue as related to adherence and health literacy in patients with rheumatoid arthritis J. G. Kuipers1, M. Koller2, F. Zeman2, K.…
Abstract Number: 614 • 2016 ACR/ARHP Annual Meeting
Canadian Study of Outcomes in Adalimumab (HUMIRA®) Patients with Support for Adherence – Results from the Companion Study
Sebastien Gerega¹, Brad Millson¹, Louis Bessette², John Marshall³, Gerald Lebovic^4,5, Michael Sung¹, Driss Oraichi¹, Sandra Gazel⁶, Tania Gaetano⁶, Martin Latour⁶ and Marie-Claude Laliberté⁶, ¹IMS Brogan, Kirkland, QC, Canada, ²Centre Hospitalier de l'Université Laval, Quebec, QC, Canada, ³Department of Medicine, Division of Gastroenterology, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada, ⁴Applied Health Research Centre, St. Michael’s Hospital, Toronto, ON, Canada, ⁵Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁶AbbVie, Inc., St.Laurent, QC, Canada
Background/Purpose: Adalimumab (ADA) is a TNF-alpha inhibitor indicated for use in various inflammatory autoimmune diseases including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis…
Abstract Number: 709 • 2016 ACR/ARHP Annual Meeting
Development of a Novel Medication Adherence Prediction Model for Patients with Ankylosing Spondylitis Based on Results from a Global Clinical Study
Philip J Mease¹, Josef S. Smolen², Dafna D Gladman³, Joachim Sieper⁴, John Weinman⁵, Julia Sommer⁶, Pascal Nurwakagari⁷ and Maja Hojnik⁸, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medical University of Vienna, Vienna, Austria, ³University of Toronto, Toronto, ON, Canada, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵King's College, London, United Kingdom, ⁶GKM Gesellschaft für Therapieforschung mbH, Munich, Germany, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸AbbVie, Ljubljana, Slovenia
Background/Purpose: Adherence to systemic therapies, such as tumor necrosis factor inhibitors (TNFi’s), is affected by various factors and may be critical for optimal disease outcomes…
Abstract Number: 755 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Blood Level Monitoring in a Predominantly Hispanic Systemic Lupus Erythematosus Cohort
James Miceli¹, Kayla Neville¹, Laura Geraldino-Pardilla² and Anca D. Askanase³, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ³Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Hydroxychloroquine (HCQ) is recommended for all patients with SLE. While patient reported adherence rates are between 51-64%, blood HCQ level testing may be a…
Abstract Number: 1159 • 2016 ACR/ARHP Annual Meeting
Use of Rheumatology-Specific Patient Navigators for DMARD Adherence: Results from a Pilot Intervention
Candace H. Feldman¹, Alyssa Wohlfahrt², Anarosa Campos³, Joshua Gagne⁴, Maura D. Iversen⁵, Elena Massarotti⁶, Ichiro Kawachi⁷ and Daniel H. Solomon⁸, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁵Northeastern University, Department of Physical Therapy, and Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁶Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Social and Behavioral Sciences, Harvard T. H. Chan School of Public Health, Boston, MA, ⁸Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Adherence to DMARDs is suboptimal and declines over time, preventing patients from reaching remission. Patient navigators, non-health professionals trained in advocacy, care coordination and…
Abstract Number: 1172 • 2016 ACR/ARHP Annual Meeting
Azathioprine and Mycophenolate Mofetil Adherence in a Nationwide Medicaid Cohort with Systemic Lupus Erythematosus
Candace H. Feldman¹, Jamie E. Collins², Zhi Zhang³, Ichiro Kawachi⁴, Daniel H. Solomon⁵ and Karen H. Costenbader⁶, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham & Women's Hospital, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Social and Behavioral Sciences, Harvard T. H. Chan School of Public Health, Boston, MA, ⁵Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Azathioprine (AZA) and mycophenolate mofetil (MMF) are commonly used immunosuppressants for moderate-to-severe SLE. Overall adherence among SLE patients has been shown to be poor…
Abstract Number: 1260 • 2016 ACR/ARHP Annual Meeting
Association of Traditional Chinese Medicine Use and Adherence to Prescribed Western Medications in Chinese-American Rheumatology Patients
Kai Sun¹, Henghe Tian², Yuo-Yu Lee³, Jennifer Leng⁴ and Lisa Mandl⁵, ¹Internal Medicine, Hospital for Special Surgery, New York, NY, ²Internal Medicine, New York University School of Medicine, New York, NY, ³Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Immigrant Health and Cancer Disparities laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, ⁵Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Chinese-Americans are one of the fastest growing immigrant groups in the US. They often use Traditional Chinese Medicine (TCM), but whether that affects medication…
Abstract Number: 1737 • 2016 ACR/ARHP Annual Meeting
Adherence to Subcutaneous Biological Therapies Among Inflammatory Arthropaty Patients from a University Hospital
Catalina Gómez-Arango¹, M. Luz García-Vivar¹, Montserrat Alonso-Diez², M. Milagros Alvarez-Lavin², Eva Galindez-Agirregoikoa³, Olaia Fernández-Berrizbeitia³, Esther Ruíz-Lucea¹, Juan María Blanco-Madrigal¹, Jose Francisco Garcia-Llorente¹, Lidia Estopiñán-Fortea³, Ignacio Torre-Salaberri⁴, Edurne Guerrero-Basterretxea³, Itziar Calvo-Zorrilla³, Amaia Bilbao-González⁵ and Natalia Rivera-García⁵, ¹Rheumatology, Rheumatology Department, Basurto University Hospital, Bilbao, Spain, ²Pharmacy Department, Basurto University Hospital, Bilbao, Spain, ³Rheumatology Department, Basurto University Hospital, Bilbao, Spain, ⁴Rheumaytology, Rheumatology Department, Basurto University Hospital, Bilbao, Spain, ⁵Research Department, Basurto University Hospital, Bilbao, Spain
Background/Purpose: Rheumatic inflammatory arthropaties such as Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Spondyloarthrities (SpA) are chronic diseases that require adequate therapies, sometimes biological drugs,…
Abstract Number: 2010 • 2016 ACR/ARHP Annual Meeting
Predictive Factors of Adherence to Treatment in an International Prospective Study of Blood Hydroxychloroquine Levels in SLE Patients with Flares
Nathalie Costedoat-Chalumeau¹, Frédéric A. Houssiau², Peter M. Izmirly³, Véronique Le Guern⁴, Sandra V. Navarra⁵, Meenakshi Jolly⁶, Guillermo RUIZ-IRASTORZA⁷, Eric Hachulla⁸, Nancy Agmon-Levin⁹, Yehuda Shoenfeld¹⁰, Francesca Dall'Ara¹¹, Jill P. Buyon¹², Christophe Deligny¹³, Ricard Cervera¹⁴, Estibaliz Lazaro¹⁵, Holy Bezanahary¹⁶, Gabriel Baron¹⁷, Gaëlle Leroux¹⁸, Nathalie Morel⁴, Jean-Francois Viallard¹⁹, Christian Pineau²⁰, Lionel Galicier²¹, Ronald van Vollenhoven²², Angela Tincani²³, Hanh Nguyen²⁴, Guillaume Gondran²⁵, Noel Zahr²⁶, Jacques Pouchot²⁷, Jean Charles Piette²⁸, Michelle Petri²⁹ and David A. Isenberg³⁰, ¹Internal Medicine, Cochin University Hospital, Paris, France, ²Rheumatology, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ³New York University School of Medicine, New York, NY, ⁴Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁵Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ⁶Rush, Chicago, IL, ⁷Cruces University Hospital, Barakaldo, Spain, ⁸Internal Medicine, Lille University Hospital, Lille, France, ⁹Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Aviv, Israel, ¹⁰Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel Hashomer, Israel Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel, ¹¹University of Pavia, Pavia, Italy, ¹²Medicine, New York University School of Medicine, New York, NY, ¹³Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique, ¹⁴Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, ¹⁵Centre François Magendie, CHU de Bordeaux, Pessac, France, ¹⁶Internal Medicine, University Hospital of Limoges, Limoges, France, ¹⁷Hôpital Hôtel Dieu, Paris, France, ¹⁸Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ¹⁹Internal Medecine, Haut Lévèque Hospital, Bordeaux, France, ²⁰Rheumatology, MUHC, Montreal, QC, Canada, ²¹Clinical Immunology, St Louis Hospital, Paris, France, ²²Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²³Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²⁴Centre of Rheumatology. Medicine., University College of London Hospital, london, United Kingdom, ²⁵Internal Medicine Department, Limoges, France, ²⁶Pitié Salpêtrière, Pharmacological, Pitié Salpêtrière, Paris, France, ²⁷Internal Medicine Department, European Hospital Georges Pompidou, Paris, France, ²⁸Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, ²⁹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ³⁰Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Non-adherence to treatment, a major cause of continued lupus activity and flares, may be difficult to recognize. In this international prospective study, we evaluated…
Abstract Number: 2039 • 2016 ACR/ARHP Annual Meeting
Assessing Barriers to Uveitis Screening in Patients with JIA: A Qualitative Study
Laura Ballenger¹, Kyla Driest² and Stacy P. Ardoin³, ¹Nationwide Children's Hospital, Columbus, OH, ²Rheumatology, Nationwide Children's Hospital, Columbus, OH, ³Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH
Background/Purpose: Uveitis is a major complication in patients with juvenile idiopathic arthritis (JIA) can be completely asymptomatic until vision loss develops. In order to prevent ocular…
Abstract Number: 2649 • 2015 ACR/ARHP Annual Meeting
Test-Retest Reliability of the 5-Item Compliance Questionnaire Rheumatology and Factors Influencing Its Assessment of Adherence in Patients with Rheumatoid Arthritis
Raquel Sweezie¹, Mary J. Bell², Charles Goldsmith³, Imy Chiu¹, Anna Gutlin¹ and Sharron Sandhu¹, ¹Rheumatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ²Rheum Div/Univ of Toronto, University of Toronto, Toronto, ON, Canada, ³Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: Adherence to disease modifying anti-rheumatic drug (DMARD) therapy is suboptimal in patients with rheumatoid arthritis (RA). Efficient, low-cost measures are required for optimal monitoring…
Abstract Number: 2758 • 2015 ACR/ARHP Annual Meeting
Clinical Utility and Factors Associated with Certolizumab Pegol Drug Levels and Anti-Drug Antibodies in the Long-Term Treatment of Rheumatoid Arthritis
Meghna Jani¹, Hector Chinoy^1,2, John Isaacs³, Ann W. Morgan⁴, Anthony Wilson⁵, Kimme L. Hyrich⁶, Darren Plant^1,2 and Anne Barton^1,7, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ³National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, ⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds & Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Infection & Immunity, University of Sheffield, Sheffield, United Kingdom, ⁶Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom
Background/Purpose: Up to 40% of RA patients on anti-TNF agents fail to respond either due to primary or secondary inefficacy. One explanation is immunogenicity leading…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.